What’s Happening in the 2026 Ebola Outbreak in the Democratic Republic of Congo

Subsequent updates from European and international health agencies showed the outbreak expanding rapidly. By around 20 May 2026, reports indicated nearly 600 suspected cases and about 139 deaths, including dozens of laboratory‑confirmed infections.

Later situation summaries reported hundreds of suspected cases and more than 80 confirmed infections in the DRC, along with two confirmed imported cases in Uganda, including one death.

Health officials caution that these numbers may change frequently as surveillance improves and more cases are confirmed through laboratory testing.

The Bundibugyo strain — why this outbreak is concerning

The virus responsible is Bundibugyo ebolavirus (BDBV), one of several species of Ebola viruses that infect humans. Laboratory testing by the DRC’s National Institute of Biomedical Research confirmed the strain in May 2026.

The strain raises concern for several reasons:

• No licensed vaccine or specific treatment exists for Bundibugyo virus, unlike the Zaire strain of Ebola, for which vaccines and therapies have been developed.
• The virus can produce high case‑fatality outbreaks, historically ranging roughly from about 30% to 50% depending on conditions and care.
• Bundibugyo outbreaks are rare, with only a small number documented since the virus was first identified in 2007.

Without established vaccines or targeted therapies, public‑health control measures such as isolation, contact tracing, and infection prevention become even more critical.

Where the outbreak is spreading

The epicenter of the outbreak is Ituri Province in northeastern DRC, where the first cluster of cases was detected.

From there, health authorities have identified spread or linked cases in several locations:

• Ituri Province: the primary outbreak zone where the earliest clusters occurred.
• North Kivu Province: additional confirmed cases linked to travel from affected areas.
• South Kivu Province: a confirmed case was reported in late May, indicating geographic spread within eastern DRC.
• Uganda: two imported confirmed cases were reported in Kampala involving travelers from DRC.

The movement of people between provinces and across borders has raised concern about further regional transmission.

Why the real number of infections may be higher

Health authorities believe the true number of infections could be higher than official counts for several reasons.

First, the outbreak began in remote areas of eastern DRC, where healthcare infrastructure and diagnostic capacity are limited. Delays in testing or reporting can allow cases to accumulate before they are officially recorded.

Second, the first alert to the WHO described an unknown illness with unusually high mortality, including deaths among healthcare workers, suggesting the disease circulated for some time before Ebola was confirmed.

Finally, the region faces logistical and security challenges that can complicate surveillance, contact tracing, and laboratory confirmation. Limited data early in the outbreak means suspected cases may significantly exceed confirmed ones.

How the outbreak was first detected

The outbreak traces back to reports received by WHO on 5 May 2026 of an unexplained illness with high mortality in the Mongbwalu Health Zone of Ituri Province, including multiple deaths among healthcare workers.

Rapid response teams were deployed to investigate the cluster. Laboratory testing conducted at the National Institute of Biomedical Research in Kinshasa confirmed the illness was caused by the Bundibugyo strain of Ebola.

Following confirmation:

• 15 May 2026: DRC and Uganda formally declared Ebola outbreaks.
• 16 May 2026: the WHO Director‑General determined the event met the criteria for a Public Health Emergency of International Concern under international health regulations.
• 17 May 2026: the WHO publicly announced the emergency declaration.

International response and travel measures

Global health organizations rapidly mobilized resources after confirmation of the outbreak.

Key response measures include:

• Deployment of international response teams, including epidemiologists, infection‑control specialists, and laboratory experts to support containment efforts.
• Enhanced surveillance and contact tracing across affected provinces and border regions.
• Travel health measures, including enhanced screening and monitoring for travelers from affected countries and certain entry restrictions implemented by U.S. authorities.
• International coordination through WHO emergency mechanisms to share data and support affected countries.

WHO and partner agencies have also called for clinical trials of candidate vaccines and therapeutics designed specifically for the Bundibugyo strain.

Treatments, vaccines, and fatality risk

Unlike the more common Zaire ebolavirus, which has an approved vaccine (ERVEBO), no licensed vaccine or targeted therapy currently exists for Bundibugyo virus disease.

Treatment therefore focuses on supportive medical care, including hydration, symptom management, and treatment of complications—interventions that can significantly improve survival if patients receive early care.

Historically, Bundibugyo outbreaks have shown case‑fatality rates roughly around 30% or higher, though the exact rate varies widely depending on the quality of care and how early cases are detected.

The bigger picture

The 2026 outbreak is the 17th recorded Ebola outbreak in the Democratic Republic of the Congo, underscoring the country’s recurring vulnerability to emerging infectious diseases.

While the WHO considers the current outbreak a serious international public‑health threat, it has not been classified as a pandemic emergency, and health agencies say the risk to populations outside the region remains low if containment measures succeed.

The coming months will likely determine whether rapid response efforts can stop transmission—or whether the outbreak spreads further across Central and East Africa.